The Latest Cardiac and Vascular News
Newly updated recommendation extends consideration of PES into stroke rehabilitation and recovery, further advancing Phagenesis’ mission to restore swallowing function, independence and dignity after stroke NASHVILLE, Tenn., Sept. 2, 2026 /PRNewswire/ — A new 2026 guideline from the…
BB-025 produced complete, rapid reversal of BB-031 activity within five minutes and was generally safe and well-tolerated across 60 healthy volunteers RESEARCH TRIANGLE, N.C., Aug. 25, 2026 /PRNewswire/ — Basking Biosciences (Basking), a clinical-stage biopharmaceutical company…
First randomized controlled trial of an at-home, noninvasive BCI therapy for chronic stroke shows more than half of patients achieved clinically meaningful recovery VAN NUYS, Calif., Aug. 18, 2026 /PRNewswire/ — Kandu, Inc., a commercial-stage healthcare technology company developing…
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the s
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care launches Ikon 24 Pro Guidewire, enhancing the Zoom Stroke System to support more efficient stroke procedures.
A Cambridge-founded medtech company Upfront Diagnostics Announces Global Medical Advisory Board to Accelerate Efforts in Reducing Time to Stroke Care
The American Heart Association presents Get With The Guidelines® – Stroke SILVER Plus with Target Stroke Honor Roll Elite Plus and Target Type 2 Diabetes Honor Roll award for demonstrating commitment to delivering evidence-based, life-saving stroke care. Award reflects hospital’s…
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced it has received U.S….
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced that initial patients have been enrolled in the ADAPT 2.0 Clinical Study, a prospective, multi-center, open-label, observational study evaluating the effectiveness, safety and clinical outcomes of the ADAPT 2.0 technique using the Zoom Stroke System to treat patients with acute ischemic stroke. “This study is designe
LOS ALTOS, Calif., March 4, 2026 /PRNewswire/ — XYRA LLC announces that the US Patent and Trademark Office (USPTO) has issued a patent (No. 12,551,706) protecting the use of dose adjusted budiodarone for the treatment of atrial fibrillation (AF), with monitoring to correspondingly reduce…
